This CMS page is not visible to your customers.
The scalp bears an average 110,000 hair follicles which are growing and falling on a daily basis. When the balance between the growing hair and the falling ones is altered, then hair loss starts and baldness appears.
To reverse this phenomenon referred to as alopecia, Redensyl® dramatically reactivates hair growth and decreases hair loss with clinically visible results in 3 months by:
It is a known fact that 40% of men will have noticeable hair loss (alopecia) by age 35. This number reaches 65% by 60 years of age. Women are also deeply impacted by such process: 50 to 75% suffer noticeable hair loss by age 65. Hair loss can be devastating to one’s self image and emotional well being.
The hair cycle is made of three phases:
When suffering from hair loss, the telogen phase is prolonged, and the transition to the anagen phase becomes more difficult. Hair become thinner and the percentage of hair transitioning to the telogen phase continues to increase.
The problem comes from the fact that the hair follicle stem cells (also called ORSc) located in the bulge along the hair, are less productive, and less adapted to improve the quality of the matrix (made of keratinocytes) supporting the hair follicle growth. Furthermore, the fibroblasts located in the dermal papilla (also called HFDPc) are less efficient in communicating with the stem cells, meaning that the matrix will not be renewed as it used to.
Initiating the anagen phase becomes more sluggish, and hair loss becomes a part of daily life.
Redensyl® is made of patented molecules targeting the ORSc and the HFDPc at the same time for a better efficiency:
Human fibroblasts dermal papilla cells (HFDPc) were incubated for 48 hours in a basal medium and treated with increasing doses of DHQG (the major component of Redensyl®) or bFGF as a reference.
Their metabolic activity was evaluated thanks to a XTT reduction assay.
Results: DHQG helps the HFDPc to improve their metabolic activity, for a better nourishment of the hair follicle.
EGCG2 was tested for its ability to reduce IL-8, a cytokine involved in scalp irritation. An irritated skin is more prone to hair loss. Normal human keratinocytes were put in a culture medium and were stressed using IL-1 and treated for 48h with EGCG2, a major component of Redensyl®. IL-8 in the supernatant was quantified by ELISA test.
Results: EGCG2 confirms its anti-irritation potential by inhibiting IL-8 release by 21%.
Redensyl® was tested at 1% versus Minoxidil at 1% as a benchmark reference to evaluate its potential on hair follicle growth. Hair of four male donors suffering from alopecia were maintained alive in normal hair culture conditions. After 7 and 10 days hair growth was measured compared to day 0 with pictures analysis.
Results: Redensyl® increases hair growth by +214% compared to untreated, and shows almost two times higher results than Minoxidil, the benchmark reference.
The efficiency of Redensyl® at 3% was evaluated in a double-blind test versus a placebo. Twenty six male volunteers were selected by following specific inclusion criteria: between 18 to 70 years old, brown to dark hair, with a minimum density of hair of 150 hair/cm2 and 40 telogen hair/cm2, with clinically confirmed grade 3 to 4 alopecia.
Volunteers applied the placebo or the product with 3% of Redensyl® on their whole scalp daily for 3 months.
A shaved area of 1.5cm2 was defined on each volunteer to allow the measurements on a window of 0.7cm2 at D0, D28 and D84.
Phototrichograms were realized using a NIKON camera associated with Canfield® Epiflash System and a contact plate to press hair on the scalp. Analysis were run with Photoshop CS5 extended® and permitted to define if hair were in anagen, telogen or undetermined phase.
Results: A non significant placebo effect is observed (mechanical activation of micro-circulation), with almost no more evolution after 1 month. Redensyl® increases the percentage of hair in anagen phase by 9% compared to T0 after 3 months, and decreases the percentage of hair in the telogen phase by 17% compared to T0 after 3 months.
The ratio Anagen/Telogen was evaluated by comparing the density of hair in anagen phase and in telogen phase.
Results: Redensyl® significantly increases the ratio Density of Anagen / Density of Telogen. After 3 months the ratio reaches 2.37 while the placebo shows almost no evolution after one month.
As a consequence, density of hair was also measured and was increased by an average +8% in three months while using Redensyl® at 3%.
85% of volunteers show clinical improvements. More anagen hair, a higher density, more visible hair. Examples of the clinical results of three volunteers (29 to 52 years old) treated with Redensyl® during 3 months.
A self-evaluation after 3 months was run by the volunteers.
Results: Testers claim Redensyl® at 3% reduced their hair loss, improved the capillary density by strengthening and thickening their hair after three months of treatment.
71% of the testers are satisfied by the product, and 71% of them would like to buy the product.
+10,200 hair in average in 3 months: better results than one hair transplantation procedure1.